基于网络药理学探讨党参从脾论治糖尿病胃轻瘫的作用机制
Journal: Frontiers of Chinese Medicine Research DOI: 10.12238/fcmr.v7i2.14502
Abstract
目的：糖尿病胃轻瘫(DGP)是糖尿病的常见并发症,本研究通过网络药理学技术体系,系统解析党参基于“健脾”理论治疗DGP的潜在作用路径。方法：通过多个数据库筛选党参活性成分及作用靶点,结合GeneCards、OMIM等数据库获取DGP相关靶点,构建“成分-靶点-疾病”网络,进行富集分析,并探讨党参从脾论治DGP的作用机制。结果：筛选获得党参活性成分21个,其作用靶点244个,DGP疾病靶点965个,党参与DGP共同靶点29个。得到党参治疗DGP的主要成分为木樨草素、7-甲氧基-2-甲基-异黄酮、豆甾醇、黄豆黄素等。KEGG通路富集分析表明,共同靶点主要富集于癌症通路、钙信号通路、HIF-1信号通路、cAMP/CGMP-PKG通路及PPAR、NF-κB、JAK-STAT等代谢与炎症调控通路。结论：党参治疗DGP具有多靶点、多成分等特点。
Keywords
网络药理学；党参；糖尿病胃轻瘫；从脾论治
Funding
云南省教育厅-校院联合专项(编号：XYLH202338)。
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] ScholJ,Wauters L,Dickman R, et al. United European Gastroenterology(UEG) and European Society for Neurogastroe nterology and Motility ( ESNM) consensus on gastroparesis[J]. Neurogastroenterol Motil,2021,33(8):e14237.
[2] Petri M, Singh I, Baker C, et al. Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies,with a focus on ghrelin receptor agonists. J Diabe tes Complications.2021;35(2):107733.
[3] 王泽,王秋虹,林兰.林兰教授治疗糖尿病胃轻瘫经验拾粹[J].四川中医,2019,37(7):8-11.
[4] Nie Q,Chen H,Hu J,et al.Dietary compounds and tradit ional Chinese medicine ameliorate type 2 diabetes by modula ting gut microbiota.Crit Rev Food Sci Nutr.2019;59 (6):848-863.
[5] 刘培.基于PI3K/AKT通路研究四君子汤调节2型糖尿病糖脂代谢紊乱的作用机制[D].山西中医药大学,2020.
[6] 黄圆圆,张元,康利平,等.党参属植物化学成分及药理活性研究进展[J].中草药,2018,49(01):239-250.
[7] 仁增加,李啟恩,切羊让忠,等.基于“味性化味-网络药理-分子对接”的藏药四味姜黄汤防治糖尿病肾病的作用机制预测[J].中成药,2022,44(02):640-646.
[8] 何婷,王亚楠,王银洁,等.基于网络药理学和分子对接探讨青龙衣治疗白癜风的物质基础及作用机制[J].亚太传统医药,2021,17(12):182-189.
[9] 冷玉琳,刘晓可,朱建伟,等.基于“脾气散精”理论探讨助脾散精法对代谢性疾病内质网应激的调节作用[J].中医杂志,2020,61(10):866-869.
[10] 谢浩然,廖红雨,龚晓媛,等.糖尿病胃轻瘫的发病机制和治疗研究进展[J].胃肠病学,2020,25(12):759-763.
[11] 孟醒,董晓红,张艳丽,等.糖尿病胃轻瘫中西医诊治概述[J].辽宁中医药大学学报,2022,24(1):172-178.
[12] 谢琦,程雪梅,胡芳弟,等.党参化学成分、药理作用及质量控制研究进展[J].上海中医药杂志,2020,54(8):94-104.
[13] 刘良,王建华,侯宁.党参煎剂抗胃黏膜损伤作用观察[J].中药药理与临床,1989,5(2):11-14.
[14] 刘良,王建华,胡燕,等.党参及其有效成分抗胃黏膜损伤作用与机制研究II.党参部位提取物抗胃黏膜损伤作用观察[J].中药药理与临床,1989,5(3):11-14.
[15] 王继双,何焱,张文静,等.木犀草素的药理作用研究进展[J].生命科学,2013,25(6):560-565.
[16] 林烨,柳丽,孙静,李言.木犀草素防治糖尿病的作用机制研究进展[J].中药药理与临床,2024,40(07):112-118.
[17] WANG Y,JIANG H,WANG L,et al.Luteolin ameliorates lop eramide-induced functional constipation Res,2023,56:e12466.
[18] Kwon E Y,Jung U J, Park T, et al. Luteolin attenuates hepatic steatosis and insulin resistance through the interpl ay between the liver and adipose tissue in mice with dietinduced obesity[J].Diabetes,2015,64(5):1658-1669.
[19] AMBASTA RK, GUPTA R, KUMAR D, et al. Can luteolin bea ther apeutic molecule for both colon cancer and diabetes? [J].Briefings in Functional Genomics,2018,18(4):230-239.
[20] AHMED QU,ALI AHM,MUKHTAR S,et al.Medicinal potential of isoflavonoids:Polyphenols that may cure diabetes[J].Molecu les,2020,25(23):5491.
[21] Cipollone F,Iezzi A,Fazia M,Zucchelli M,Pini B, Cuccur ullo C, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.Circulation.2003;108:1070-7.
[22] LIU C,FENG X, LI Q, et al.Adiponectin,TNF-α and infla mmatory cytokines and risk of type 2 diabetes: A systematic review and meta analysis[J].Cytokine,2016,86:100-109.
[23] 陈永熙,王伟铭,周同,等.PPAR-γ作用及其相关信号转导途径[J].细胞生物学杂志,2006(03):382-386.
[24] 李意奇,高健美,龚其海.以过氧化物酶体增殖物激活受体为靶点治疗2型糖尿病的药物研究进展[J].遵义医科大学学报,2023,46(02):214-220.
[25] YangJ, Zhou Y, Guan Y. PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases. Curr Opin Nephrol Hypertens.2012;21(1):97-105.
[26] 史银萍.基于数据挖掘和网络药理学的中药治疗糖尿病性胃轻瘫的用药规律和作用机制研究[D].湖北中医药大学,2023.
[2] Petri M, Singh I, Baker C, et al. Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies,with a focus on ghrelin receptor agonists. J Diabe tes Complications.2021;35(2):107733.
[3] 王泽,王秋虹,林兰.林兰教授治疗糖尿病胃轻瘫经验拾粹[J].四川中医,2019,37(7):8-11.
[4] Nie Q,Chen H,Hu J,et al.Dietary compounds and tradit ional Chinese medicine ameliorate type 2 diabetes by modula ting gut microbiota.Crit Rev Food Sci Nutr.2019;59 (6):848-863.
[5] 刘培.基于PI3K/AKT通路研究四君子汤调节2型糖尿病糖脂代谢紊乱的作用机制[D].山西中医药大学,2020.
[6] 黄圆圆,张元,康利平,等.党参属植物化学成分及药理活性研究进展[J].中草药,2018,49(01):239-250.
[7] 仁增加,李啟恩,切羊让忠,等.基于“味性化味-网络药理-分子对接”的藏药四味姜黄汤防治糖尿病肾病的作用机制预测[J].中成药,2022,44(02):640-646.
[8] 何婷,王亚楠,王银洁,等.基于网络药理学和分子对接探讨青龙衣治疗白癜风的物质基础及作用机制[J].亚太传统医药,2021,17(12):182-189.
[9] 冷玉琳,刘晓可,朱建伟,等.基于“脾气散精”理论探讨助脾散精法对代谢性疾病内质网应激的调节作用[J].中医杂志,2020,61(10):866-869.
[10] 谢浩然,廖红雨,龚晓媛,等.糖尿病胃轻瘫的发病机制和治疗研究进展[J].胃肠病学,2020,25(12):759-763.
[11] 孟醒,董晓红,张艳丽,等.糖尿病胃轻瘫中西医诊治概述[J].辽宁中医药大学学报,2022,24(1):172-178.
[12] 谢琦,程雪梅,胡芳弟,等.党参化学成分、药理作用及质量控制研究进展[J].上海中医药杂志,2020,54(8):94-104.
[13] 刘良,王建华,侯宁.党参煎剂抗胃黏膜损伤作用观察[J].中药药理与临床,1989,5(2):11-14.
[14] 刘良,王建华,胡燕,等.党参及其有效成分抗胃黏膜损伤作用与机制研究II.党参部位提取物抗胃黏膜损伤作用观察[J].中药药理与临床,1989,5(3):11-14.
[15] 王继双,何焱,张文静,等.木犀草素的药理作用研究进展[J].生命科学,2013,25(6):560-565.
[16] 林烨,柳丽,孙静,李言.木犀草素防治糖尿病的作用机制研究进展[J].中药药理与临床,2024,40(07):112-118.
[17] WANG Y,JIANG H,WANG L,et al.Luteolin ameliorates lop eramide-induced functional constipation Res,2023,56:e12466.
[18] Kwon E Y,Jung U J, Park T, et al. Luteolin attenuates hepatic steatosis and insulin resistance through the interpl ay between the liver and adipose tissue in mice with dietinduced obesity[J].Diabetes,2015,64(5):1658-1669.
[19] AMBASTA RK, GUPTA R, KUMAR D, et al. Can luteolin bea ther apeutic molecule for both colon cancer and diabetes? [J].Briefings in Functional Genomics,2018,18(4):230-239.
[20] AHMED QU,ALI AHM,MUKHTAR S,et al.Medicinal potential of isoflavonoids:Polyphenols that may cure diabetes[J].Molecu les,2020,25(23):5491.
[21] Cipollone F,Iezzi A,Fazia M,Zucchelli M,Pini B, Cuccur ullo C, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.Circulation.2003;108:1070-7.
[22] LIU C,FENG X, LI Q, et al.Adiponectin,TNF-α and infla mmatory cytokines and risk of type 2 diabetes: A systematic review and meta analysis[J].Cytokine,2016,86:100-109.
[23] 陈永熙,王伟铭,周同,等.PPAR-γ作用及其相关信号转导途径[J].细胞生物学杂志,2006(03):382-386.
[24] 李意奇,高健美,龚其海.以过氧化物酶体增殖物激活受体为靶点治疗2型糖尿病的药物研究进展[J].遵义医科大学学报,2023,46(02):214-220.
[25] YangJ, Zhou Y, Guan Y. PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases. Curr Opin Nephrol Hypertens.2012;21(1):97-105.
[26] 史银萍.基于数据挖掘和网络药理学的中药治疗糖尿病性胃轻瘫的用药规律和作用机制研究[D].湖北中医药大学,2023.
Copyright © 2025 黄媱, 杨雅萍, 杨婷, 陈霞
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License